Recordati company profile
Company profile
Recordati has 4,700 employees and is headquartered in Milan, Italy.
With revenue of EUR 2.6 billion in the fiscal year ended 31 December 2025, the group researches, develops, produces and sells pharmaceuticals through two business areas, Specialty and Primary Care and Rare Diseases. Its portfolio includes treatments for rare conditions such as maple syrup urine disease, Cushing's syndrome and cystinosis, with Carbaglu, Cystadrops and Isturisa, alongside cardiovascular and urology products such as Zanidip and Urorec, and oncology products including Eligard and Fotivda. Sales are made in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal and North Africa, as well as in other international markets.
Revenue rose 11.8% compared with the previous year, and net profit reached EUR 443.6 million in the fiscal year ended 31 December 2025. The group employs 4,700 people. It was founded in 1926, and its head office is in Milan, Italy.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Italy
- Headquarters
- Via Matteo Civitali,1, 20148, Milan
- Employees
- 4,700
- Chief executive
- Robert Koremans
- Founded
- 1926
- Fiscal year
- January - December
- Listing
- REC · Borsa Italiana
- Indices
- FTSE MIB
- Currency
- EUR
- ISIN
- IT0003828271
- Website
- recordati.com
Recordati and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| RecordatiREC | Italy | $12.09B | 4,700 | 32.6% | 21.1 |
| OrionORNAV | Finland | $15.84B | 4,215 | 38.1% | 22.0 |
| GrifolsGRF | Spain | $8.71B | 25,000 | 18.9% | 16.4 |
| VirbacVIRP | France | $3.27B | 6,442 | 15.8% | 19.1 |
| BayerBAYN | Germany | $61.54B | 87,775 | 16.5% | — |
| GSKGSK | United Kingdom | $102.04B | 66,841 | 30.5% | 18.0 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
